Nonalcoholic Fatty Liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: one pill per day containing 500 million Lactobacillus bulgaricus and Streptococcus thermophilus (Nutricion Medica, SL, Spain) with the brand name Lactofer of bio-fe
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: People between 20 and 75 years old with confirmed fatty liver in Persian Cohort of Mashhad
Exclusion criteria
Exclusion criteria: •Liver failure • Suffering from hepatitis (viral, autoimmune, metabolic, medicinal) • History of alcohol consumption • People with ALT or AST more than 5 times normal • • Pregnant people •Taking drugs that can cause hepatic steatosis, including antiarrhythmic drugs (Amiodarone) ), anti-metabolite antineoplastic drugs (methotrexate), hormonal antineoplastic drugs (tamoxifen), corticosteroids, anticonvulsant drugs, antiretroviral drugs • use of antihypertensive drugs, vastatins) • known hereditary defects (iron and copper). Storage diseases and alpha 1 antitrypsin deficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of people with non-alcoholic fatty liver disease with a score of at least 2. Timepoint: Examining tests three months after start of using probiotics. Method of measurement: Liver tests including sugar and fat profile, ultrasound of the liver and bile ducts. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzaneh Hakimi
Mashhad University of Medical Sciences
Outcome results
None listed